Stockscreener 앱 받기
10.00
1.96%
-0.2001
전일 마감가:
$10.20
열려 있는:
$10.6
하루 거래량:
13,187
Relative Volume:
1.19
시가총액:
$6.68M
수익:
-
순이익/손실:
$-18.82M
주가수익비율:
-0.3206
EPS:
-31.1883
순현금흐름:
$-14.79M
1주 성능:
-2.25%
1개월 성능:
+1.73%
6개월 성능:
-17.64%
1년 성능:
-93.08%
1일 변동 폭
$10.00
$10.60
1주일 범위
$9.6942
$10.99
52주 변동 폭
$8.67
$196.70
Envveno Medical Corp Stock (NVNO) Company Profile
명칭
Envveno Medical Corp
전화
949-261-2900
주소
70 DOPPLER, IRVINE
Compare NVNO vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
10.00 | 6.68M | 0 | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp 주식(NVNO)의 최신 뉴스
enVVeno Medical Corp (NVNO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
enVVeno Medical Corp (NVNO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
enVVeno Medical Corp (NVNO) Institutional Confidence - TradingKey
enVVeno Medical Corp (NVNO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
enVVeno Medical Corp (NVNO) Valuation: PE, PB & Fair Value Analysis - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
enVVeno Medical Corp (NVNO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical (NVNO) Retreats 1.96% as Stock Navigates Key Support at $9.50Value Stock Ideas - newsline.com
Insider Selling: Francis Duhay Sells Shares of enVVeno Medical C - GuruFocus
Director at enVVeno Medical (NASDAQ: NVNO) sells 140 shares under Rule 10b5-1 plan - Stock Titan
[144] enVVeno Medical Corp SEC Filing - Stock Titan
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System - PhillyBurbs
enVVeno Medical Announces Reverse Stock Split - Great Falls Tribune
enVVeno Medical (NVNO) Holds Steady at $10.75 – Support and Resistance Define Neutral RangeUndervalued Stocks - newsline.com
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series - marketscreener.com
First FDA IDE venous valve study: enVVeno CEO Q&A June 9 - Stock Titan
enVVeno Medical (NVNO) Edges Higher as Stock Tests Key Resistance Near $11.90Throwback Trade - The Legal Advocate
enVVeno Medical (NVNO) Edges Lower as Stock Holds Above Key SupportFRAMA Signal - newsline.com
enVVeno Medical (NVNO) Slips 1.03% as Price Hovers Near Key Support at $10.47Factor Crowding - newsline.com
NVNO Q3 2025 Earnings: Narrower Net Loss Surpasses Analyst ExpectationsEarnings Season Review - The Legal Advocate
This Tiny Medical-Device Stock Is Back Above $11. Its Next FDA Test Is the Whole Trade - Bez Kabli
enVVeno Medical Q3 2025 Earnings: Narrower Loss Beats Expectations as Clinical Programs AdvanceProfit Margin Analysis - The Legal Advocate
enVVeno Medical (NVNO) Q3 2025 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Progress - newsline.com
enVVeno Medical (NVNO) Edges Higher: Analyzing Recent Price Action and Key LevelsWave Truncation - Newser
Perceptive entities disclose 9.99% stake in enVVeno (NASDAQ: NVNO) - Stock Titan
This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It? - MSN
Kingdon group holds 36,166 shares in enVVeno (NASDAQ: NVNO) - Stock Titan
Number of shareholders of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment - The Joplin Globe
First-ever U.S. venous valve trial could address DVI in 3M Americans - Stock Titan
TradingKey - TradingKey
What enVVeno (NVNO) is doing that smart investors recognize (-2.26%) 2026-05-08Stock Surge - Newser
enVVeno Medical sees cash runway into 3Q27 - TipRanks
enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter - TipRanks
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year - TipRanks
enVVeno Reports Having $25M Cash on Hand in Q1 Earnings - Orange County Business Journal
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System - IndyStar
With $25M on hand, enVVeno moves toward first U.S. venous valve study - Stock Titan
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
enVVeno Medical (NVNO) trims Q1 loss and secures FDA IDE for pivotal enVVe TAVVE study - Stock Titan
One enVVeno Medical Insider Raised Their Stake In The Previous Year - Yahoo Finance
enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve - MedTech Intelligence
enVVeno Medical secures FDA IDE approval for venous valve study - Medical Device Network
enVVeno Medical (NVNO) Secures FDA IDE Approval for Pivotal Stud - GuruFocus
enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study - TipRanks
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve - BioSpace
enVVeno Medical Wins FDA IDE for TAVVE Trial - TipRanks
Envveno Medical Corp (NVNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):